相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation
Naoharu Yagi et al.
HEART AND VESSELS (2020)
Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review
Joana Santos et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE-AF
Jane S. Saczynski et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2020)
Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing
Min Soo Cho et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
Alexandros Briasoulis et al.
BMC CARDIOVASCULAR DISORDERS (2020)
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
Mark Alberts et al.
STROKE (2020)
Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study
Daniele Pastori et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
Alan John Camm et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study
Motoyasu Miyazaki et al.
JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2020)
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population
Maria Cerda et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis
Chris Wilkinson et al.
AGE AND AGEING (2019)
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1
Craig I. Coleman et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Frailty and atrial fibrillation: A systematic review
Emanuele R. Villani et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2018)
Global Prospective Safety Analysis of Rivaroxaban
Paulus Kirchhof et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
Benjamin A. Steinberg et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing
Souad Moudallel et al.
FRONTIERS IN PHARMACOLOGY (2018)
Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain
Edelmira Marti et al.
FUTURE CARDIOLOGY (2018)
Drug persistence and outcomes in a cohort of patients with nonvalvular atrial fibrillation treated with rivaroxaban after 2 years of follow-up in clinical practice
Alejandro Isidoro Perez Cabeza et al.
FUTURE CARDIOLOGY (2018)
Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke
Juan Jose Cerezo-Manchado et al.
FUTURE CARDIOLOGY (2018)
Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice
David Brun Guinda et al.
FUTURE CARDIOLOGY (2018)
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence
Matthew R. Weir et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice
Gonzalo Baron-Esquivias et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2017)
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
Fatima Khan et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2016)
Atrial fibrillation and chronic kidney disease: focus on rivaroxaban
Vivencio Barrios et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
分享论文
